Vaxart Gestione

Criteri Gestione verificati 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Steven Lo

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1yr
Proprietà del CEO	n/a
Durata media del management	3.1yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Steven Lo (57 yo)

1yr

Mandato

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sean Tucker	Senior VP & Chief Scientific Officer	15.1yrs	US$1.14m	0.18% MX$ 4.3m
James Cummings	Chief Medical Officer	3.6yrs	US$1.17m	0.071% MX$ 1.7m
Steven Lo	President	1yr	Nessun dato	Nessun dato
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2.3yrs	Nessun dato	0.041% MX$ 965.2k
Raymond Stapleton	Chief Technology Officer	2.6yrs	Nessun dato	Nessun dato
Edward Berg	Senior VP & General Counsel	3.1yrs	Nessun dato	0.056% MX$ 1.3m
Laurie Hastings	Senior Vice President of Human Resources	less than a year	Nessun dato	Nessun dato
Shaily Garg	Senior Vice President of Clinical Development & Project Management	5yrs	Nessun dato	Nessun dato
Rajesh Kapoor	Senior Vice President of Quality	4.2yrs	Nessun dato	Nessun dato

3.1yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di VXRT * è considerato esperto (durata media dell'incarico 3.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Steven Lo	President	1yr	Nessun dato	Nessun dato
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
Elaine Heron	Independent Director	2.6yrs	US$89.08k	0.011% MX$ 256.6k
Michael Finney	Independent Chairman of the Board	7.1yrs	US$109.57k	0.29% MX$ 7.0m
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
David Wheadon	Independent Director	3.9yrs	US$93.72k	0.0065% MX$ 153.9k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
William Watson	Independent Director	2.6yrs	US$94.76k	0.023% MX$ 546.2k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.6yrs	Nessun dato	Nessun dato

3.6yrs

Durata media

69.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VXRT * sono considerati esperti (durata media dell'incarico 3.6 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/03/22 23:18
Prezzo dell'azione a fine giornata	2024/12/23 00:00
Utili	2024/12/31
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Vaxart, Inc. è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
null null	Oppenheimer & Co. Inc.

Vaxart Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Vaxart Receives a Letter from the Office of the General Counsel of Nasdaq

Richard John Burgess Responds to Vaxart’s Governance Announcements

Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine Candidate

Richard John Burgess Files an Exempt Solicitation Statement with Vaxart

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock Split

Richard John Burgess Oppose Vaxart’s Latest Reverse Stock Split

Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI Index

Vaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08

Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Director recently bought Mex$294k worth of stock

High number of new and inexperienced directors